Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Halozyme Therapeutics, Inc.    HALO

News SummaryMost relevantAll newsSector newsTweets

Halozyme Therapeutics, Inc. : Halozyme to Host First Quarter 2012 Financial Results Conference Call

share with twitter share with LinkedIn share with facebook
share via e-mail
04/30/2012 | 10:20pm CEST

SAN DIEGO, April 30, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics

SOURCE Halozyme Therapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
07/20 HALOZYME THERAPEUTICS : Initiation Of Clinical Trial Collaboration Evaluating Ha..
07/20 HALOZYME THERAPEUTICS : Genentech collaborate on pancreatic cancer trial
07/14 HALOZYME THERAPEUTICS : HALO) Announces Initiation Of Clinical Trial Collaborati..
07/13 HALOZYME THERAPEUTICS : Initiation Of Clinical Trial Collaboration Evaluating Ha..
07/10 HALOZYME THERAPEUTICS : To Host Second Quarter 2017 Financial Results Conference..
07/05 HALOZYME THERAPEUTICS, INC. (NASDAQ : HALO) Files An 8-K Entry into a Material D..
07/05 HALOZYME THERAPEUTICS INC : Entry into a Material Definitive Agreement (form 8-K..
06/28 HALOZYME THERAPEUTICS : Phase 2 Data In Advanced Pancreas Cancer Presented At Eu..
06/26 HALOZYME THERAPEUTICS, INC. : Halozyme FDA Action Date, Q1 Review, Analysts Outl..
06/22 HALOZYME THERAPEUTICS : FDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous ..
More news
News from SeekingAlpha
07/25 Nektar Makes A Stride Forward In Resolving Autoimmune Diseases
07/13 Halozyme up 1% premarket on start of Roche study of PEGPH20/Tecentriq combo i..
06/23 Roche Reminds Halozyme Investors Where The Money Is
06/20 WEEK 25 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge
06/04 Halozyme's PEGPH20 continues to show treatment benefit in mid-stage pancreati..